Rifaximin as a Modulator of Microbial Translocation and Immune Activation

HIV-1 Infection Clinical Trial

Official title:

A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01466595
• Other study ID #: ACTG A5286
• Secondary ID: 1U01AI068636
• Status: Completed
• Phase: Phase 2
• Start date: September 2011
• Est. completion date: November 2012

Study information

• Verified date: August 2018
• Source: AIDS Clinical Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to see whether rifaximin, an antibiotic that works in the intestines, can lower the amount of germs in the intestines of HIV infected persons. It is possible that when the amount of these germs is lowered, an HIV-infected person's immune system will become less active and will have a better chance of recovering. Also, the study will evaluate the safety of using rifaximin in HIV-infected subjects.

Description:

A5286 is a randomized, open-label, two-arm, pilot (phase II) study that evaluated whether 4 weeks of treatment with rifaximin, a non-absorbable antibiotic, decreases markers of immune activation and levels of translocated gut microbial products in HIV-1 infected subjects virally suppressed on ART with CD4+ T-cells < 350 cells/mm^3. Rifaximin were admistered to subjects for 3 weeks. Follow-up continued to week 12. The total sample size was 73 subjects. Subjects were randomized at a 2:1 ratio (rifaximin: no study treatment), using permuted blocks, without institutional balancing.

Subjects were seen through week 12 for clinical and laboratory evaluations, including plasma HIV-1 RNA, CD4+ T-cell count, and safety laboratories. Subjects had 2 baseline visits -- at pre-entry and entry. Study visits were scheduled at weeks 2, 4, 8, and 12. CD4+ T-cell counts and HIV-1 RNA were measured at all weeks; measures of activations, gut-homing markers, and soluble biomarkers were also performed at all weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: November 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• HIV-1 infection

• On ART for at least 96 weeks prior to study entry with a regimen that includes three or more antiretroviral medications. (Ritonavir = 400 mg/day will not be considered a separate antiretroviral agent.)

• No plans to change the antiretroviral regimen at least in the next 3 months after study entry.

• CD4+ cell count < 350 cells/mm3 obtained within 120 days prior to study entry at any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent.

• All previous CD4+ cell counts should be < 350 cells/mm3 for at least 96 weeks prior to study entry while subjects were on ART. (A single CD4+ cell count = 350 cells/mm3 is permitted within 96 weeks prior to study entry while subjects were on ART.)

• Documentation of HIV-1 RNA below the limit of detection (e.g., < 50 copies/mL on Roche Amplicor HIV-1 Monitor assay, < 75 copies/mL on the Versant HIV-1 RNA assay by branched DNA, < 400 copies/mL on a standard Roche Amplicor assay, < 40 copies/mL on the Abbott m2000sp/m2000rt real-time PCR test, < 48 copies/mL on the COBAS AmpliPrep/TAQMAN HIV-1 assay) verified by at least two measurements prior to study entry, one of which must be at least 48 weeks prior to study entry and one measurement that was obtained between 121 days and 48 weeks prior to study entry.

• Screening HIV-1 RNA below the limit of detection obtained within 120 days prior to study entry using a FDA -approved assay (e.g., < 50 copies/mL on Roche Amplicor HIV-1 Monitor assay, < 75 copies/mL on the Versant HIV-1 RNA assay by branched DNA, < 40 copies/mL on the Abbott m2000sp/m2000rt real-time PCR test, < 48 copies/mL on the COBAS AmpliPrep/TAQMAN HIV-1 assay). (The virologic assay must have a lower limit of detection of = 75 copies/mL.)

• All other plasma HIV-1 RNA measurements in the 48 weeks prior to study entry must be below the limit of detection. (A single detectable measurement of = 200 copies/mL is permitted if RNA levels immediately before and after are below the limits of detection for the assay.)

• Certain fasting laboratory values obtained within 45 days prior to entry as indicated in Section 4.1.9 of the protocol.

• Pre-entry peripheral blood mononuclear cell (PBMC) specimen for assay of the primary immune activation endpoint (change in CD8+ T-cells activation (%HLA-DR+CD38+CD8+ T-cells) has been obtained. Sites must receive confirmation from the processing lab via phone, e-mail, or fax, that this specimen has been entered into the ACTG's Laboratory Data Management System (LDMS).

• Female subjects of reproductive potential must have a negative serum or urine ß-HCG pregnancy test with a sensitivity of at least 50 mIU/mL performed within 24 hours prior to study entry.

• If participating in sexual activity that could lead to pregnancy, the female subject must agree to use one form of contraceptive as listed in section 4.1.11 of the protocol while receiving protocol-specified treatment and for 4 weeks after stopping the treatment.

• If the female subject is not of reproductive potential, she is eligible without requiring the use of a contraceptive. Self report is acceptable documentation of sterilization, other contraceptive methods, and menopause.

• Ability and willingness of subject or legally authorized representative to provide informed consent.

Exclusion Criteria:

• Active diarrhea (3 or more unformed stools per day) within 28 days prior to study entry (except if site investigator or primary care provider attributes diarrhea to antiretroviral or azithromycin use).

• History of or active inflammatory bowel disease.

• History of or active Clostridium difficile colitis.

• History of significant liver disease, defined as having chronic liver disease (including chronic alcoholic liver disease, hepatitis B or C), plus either: a) ascites, b) encephalopathy, or c) a Child-Pugh Score of > 7.

• Receipt of antimicrobial therapy within 30 days prior to study entry. (NOTE:

Antimicrobial use for prophylaxis of opportunistic infections, e.g., azithromycin or trimethoprim-sulfamethoxazole, is allowed.)

• Active infection requiring the use of antibiotics within 30 days prior to study entry.

• Known allergy/sensitivity or any hypersensitivity to components of study drug or their formulation (e.g., allergy to rifampin).

• Serious illness requiring systemic treatment and/or hospitalization within 14 days prior to entry.

• Use of any of the following medications for more than 3 consecutive days within the 60 days prior to study entry:

• Immunosuppressives

• Immune modulators

• Antineoplastic agents

• Probiotics

• Anticoagulants

• Vaccinations within 1 week prior to the pre-entry or study entry visits. (NOTE:

Subjects are encouraged to get the flu vaccine prior to study pre-entry visit.)

• Participation on any HIV immunotherapy/therapeutic vaccination trials within 6 months prior to study entry.

• Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.

• Breastfeeding.

Related Conditions & MeSH terms

• HIV-1 Infection

Intervention

Drug:
• Rifaximin
Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.

Locations

Country	Name	City	State
Puerto Rico	Puerto Rico-AIDS CRS (5401)	San Juan
United States	The Ponce de Leon Center CRS (5802)	Atlanta	Georgia
United States	University of Colorado Hospital CRS (6101)	Aurora	Colorado
United States	IHV Baltimore Treatment CRS (4651)	Baltimore	Maryland
United States	Alabama Therapeutics CRS (5801)	Birmingham	Alabama
United States	Beth Israel Deaconess Med. Ctr., ACTG CRS (103)	Boston	Massachusetts
United States	Brigham and Women's Hosp. ACTG CRS (107)	Boston	Massachusetts
United States	Massachusetts General Hospital ACTG CRS (101)	Boston	Massachusetts
United States	Unc Aids Crs (3201)	Chapel Hill	North Carolina
United States	Northwestern University CRS (2701)	Chicago	Illinois
United States	Rush Univ. Med. Ctr. ACTG CRS (2702)	Chicago	Illinois
United States	Univ. of Cincinnati CRS (2401)	Cincinnati	Ohio
United States	Case CRS (2501)	Cleveland	Ohio
United States	Metro Health CRS (2503)	Cleveland	Ohio
United States	The Ohio State Univ. AIDS CRS (2301)	Columbus	Ohio
United States	Duke Univ. Med. Ctr. Adult CRS (1601)	Durham	North Carolina
United States	UCLA CARE Center CRS (601)	Los Angeles	California
United States	Univ. of Miami AIDS CRS (901)	Miami	Florida
United States	Cornell CRS (7804)	New York	New York
United States	HIV Prevention & Treatment CRS (30329)	New York	New York
United States	NY Univ. HIV/AIDS CRS (401)	New York	New York
United States	New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)	Newark	New Jersey
United States	Stanford CRS (501)	Palo Alto	California
United States	Hosp. of the Univ. of Pennsylvania CRS (6201)	Philadelphia	Pennsylvania
United States	Pittsburgh CRS (1001)	Pittsburgh	Pennsylvania
United States	The Miriam Hosp. ACTG CRS (2951)	Providence	Rhode Island
United States	AIDS Care CRS (1108)	Rochester	New York
United States	Univ. of Rochester ACTG CRS (1101)	Rochester	New York
United States	Washington U CRS (2101)	Saint Louis	Missouri
United States	Ucsf Aids Crs (801)	San Francisco	California
United States	University of Washington AIDS CRS (1401)	Seattle	Washington
United States	Georgetown University CRS (GU CRS) (1008)	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
AIDS Clinical Trials Group	National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in CD8+ T-cell Activation From Baseline to Week 4	Change in CD8+ T-cell activation percent co-expressing HLA-DR and CD38 from baseline to week 4, where the baseline value is the average of pre-entry and entry values.	At baseline and 4 weeks
Secondary	Change in D-dimer From Baseline to Week 4	Change in D-dimer from baseline to week 4, where baseline value is the average of pre-entry and entry.; D-dimer is a fibrin degradation product (FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis.	At baseline and 4 weeks
Secondary	Change in IL-6 From Baseline to Week 4	Change in Interleukin (IL)-6 from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in LPS From Baseline to Week 4	Change in Lipopolysaccharide (LPS) from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in hsCRP From Baseline to Week 4	Change in High Sensitivity C-reactive Protein (Hs-CRP) from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in sCD14 From Baseline to Week 4	Change in soluble CD14 (sCD14) from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in Peripheral B7hi CD4+ T-cell From Baseline to Week 4	Change in gut-homing percent B7hi+ of CD4+ from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in %CD38+ of CD4+ From Baseline to Week 4	Change in advanced flow percent CD38+ of CD4+ from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in %CD38+ of CD8+ From Baseline to Week 4	Change in advanced flow percent CD38+ of CD8+ from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in %Ki67+ of CD4+ From Baseline to Week 4	Change in advanced flow percent Ki67+ of CD4+ from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in %Ki67+ of CD8+ From Baseline to Week 4	Change in advanced flow percent Ki67+ of CD8+ from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in %HLA-DR+/CD38+ of CD4+ From Baseline to Week 4	Change in CD4 activation percent co-expressing HLA-DR and CD38 from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in CD38+ of CD8+ MFI From Baseline to Week 4	Change in CD38+ of CD8+ MFI (Median Fluorescence Intensity) from baseline to week 4, where baseline value is the average of pre-entry and entry.; MFI measures the shift in fluorescence intensity of a population of cells. MFI values are based on control to demonstrate an increase or decrease in expression of the marker. MFI in this study was automatically calculated in FlowJo. The median is the relative intensity value below which 50% of the events are found. MFI is an arbitrary unit of relative intensity.	At baseline and 4 weeks
Secondary	Change in CD4 Count From Baseline to Week 4	Change in total CD4 T-cell from baseline to week 4, where baseline value is the average of pre-entry and entry	At baseline and 4 weeks
Secondary	Change in CD8+ T-cell Activation From Week 4 to Week 8	Change in CD8+ T-cell activation percent co-expressing HLA-DR and CD38 from week 4 to week 8	At weeks 4 and 8
Secondary	Change in D-dimer From Week 4 to Week 8	D-dimer is a fibrin degradation product (FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis.	At weeks 4 and 8
Secondary	Change in IL-6 From Week 4 to Week 8	Change in IL-6 from week 4 to week 8.	At weeks 4 and 8
Secondary	Change in LPS From Week 4 to Week 8	Change in LPS from week 4 to week 8.	At weeks 4 and 8
Secondary	Change in hsCRP From Week 4 to Week 8	Change in hsCRP from week 4 to week 8.	At weeks 4 and 8
Secondary	Change in sCD14 From Week 4 to Week 8	Change in soluble CD14 from week 4 to week 8	At weeks 4 and 8
Secondary	Change in Peripheral B7hi CD4+ T-cells From Week 4 to Week 8	Change in gut homing percent B7hi+ of CD4+ from week 4 to week 8	At weeks 4 and 8
Secondary	Change in %CD38+ of CD4+ From Week 4 to Week 8	Change in advanced flow percent CD38+ of CD4+ from week 4 to week 8	At weeks 4 and 8
Secondary	Change in %CD38+ of CD8+ From Week 4 to Week 8	Change in advanced flow percent CD38+ of CD8+ from week 4 to week 8	At weeks 4 and 8
Secondary	Change in %Ki67+ of CD4+ From Week 4 to Week 8	Change in advanced flow percent Ki67+ of CD4+ from week 4 to week 8	At weeks 4 and 8
Secondary	Change in %Ki67+ of CD8+ From Week 4 to Week 8	Change in advanced flow percent Ki67+ of CD8+ from week 4 to week 8	At weeks 4 and 8
Secondary	Change in CD4 Activation Percent From Week 4 to Week 8	Change in CD4 activation percent co-expressing HLA-DR and CD38 from week 4 to week 8	At weeks 4 and 8
Secondary	Change in CD38+ of CD8+ MFI From Week 4 to Week 8	Change in CD38+ of CD8+ median fluorescence intensity (MFI) from week 4 to week 8.; MFI measures the shift in fluorescence intensity of a population of cells. MFI values are based on control to demonstrate an increase or decrease in expression of the marker. MFI in this study was automatically calculated in FlowJo. The median is the relative intensity value below which 50% of the events are found. MFI is an arbitrary unit of relative intensity.	At weeks 4 and 8
Secondary	Change in CD4 Count From Week 4 to Week 8	Change in total CD4 T-cell count from week 4 to week 8	At weeks 4 and 8
Secondary	Change in CD8+ T-cell Activation From Week 4 to Week 12	Change in CD8+ T-cell activation percent co-expressing HLA-DR and CD38 from week 4 to week 12	At weeks 4 and 12
Secondary	Change in D-dimer From Week 4 to Week 12	D-dimer is a fibrin degradation product (FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis.	At weeks 4 and 12
Secondary	Change in IL-6 From Week 4 to Week 12	Change in IL-6 from week 4 to week 12.	At weeks 4 and 12
Secondary	Change in LPS From Week 4 to Week 12	Change in LPS from week 4 to week 12.	At weeks 4 and 12
Secondary	Change in hsCRP From Week 4 to Week 12	Change in hsCRP from week 4 to week 12.	At weeks 4 and 12
Secondary	Change in sCD14 From Week 4 to Week 12	Change in soluble CD14 from week 4 to week 12	At weeks 4 and 8
Secondary	Change in Peripheral B7hi CD4+ T-cells From Week 4 to Week 12	Change in gut homing percent B7hi+ of CD4+ from week 4 to week 12	At weeks 4 and 12
Secondary	Change in %CD38+ of CD4+ From Week 4 to Week 12	Change in advanced flow percent CD38+ of CD4+ from week 4 to week 12	At weeks 4 and 12
Secondary	Change in %CD38+ of CD8+ From Week 4 to Week 12	Change in advanced flow percent CD38+ of CD8+ from week 4 to week 12	At weeks 4 and 12
Secondary	Change in %Ki67+ of CD4+ From Week 4 to Week 12	Change in advanced flow percent Ki67+ of CD4+ from week 4 to week 12	At weeks 4 and 12
Secondary	Change in %Ki67+ of CD8+ From Week 4 to Week 12	Change in advanced flow percent Ki67+ of CD8+ from week 4 to week 12	At weeks 4 and 12
Secondary	Change in CD4 Activation Percent From Week 4 to Week 12	Change in CD4 activation percent co-expressing HLA-DR and CD38 from week 4 to week 12	At weeks 4 and 12
Secondary	Change in CD38+ of CD8+ MFI From Week 4 to Week 12	Change in CD38+ of CD8+ median fluorescence intensity (MFI) from week 4 to week 12.; MFI measures the shift in fluorescence intensity of a population of cells. MFI values are based on control to demonstrate an increase or decrease in expression of the marker. MFI in this study was automatically calculated in FlowJo. The median is the relative intensity value below which 50% of the events are found. MFI is an arbitrary unit of relative intensity.	At weeks 4 and 12
Secondary	Change in CD4 Count From Week 4 to Week 12	Change in total CD4 T-cell count from week 4 to week 12	At weeks 4 and 12
Secondary	Primary Adverse Events	Primary adverse events include all SAEs, defined according to ICH guidelines and targeted protocol events (grade 2 or higher signs and symptoms, grade 2 or higher laboratory abnormality, all diagnoses identified by the ACTG criteria for clinical events, and all events that led to a change in treatment regardless of grade).	from study enrollment until study completion at 12 weeks